Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Osemozotan (INNTooltip International Nonproprietary Name; developmental code names MKC-242 and MN-305) is a selective 5-HT1A receptor agonist with some functional selectivity, acting as a full agonist at presynaptic and a partial agonist at postsynaptic 5-HT1A receptors. 5-HT1A receptor stimulation influences the release of various neurotransmitters including serotonin, dopamine, norepinephrine, and acetylcholine. 5-HT1A receptors are inhibitory G protein-coupled receptor. Osemozotan has been shown in animal studies to have antidepressant, anxiolytic, antiobsessional, serenic, and analgesic effects. It is used to investigate the role of 5-HT1A receptors in modulating the release of dopamine and serotonin in the brain and their involvement in addiction to stimulants such as cocaine and methamphetamine.
Esimone, Charles, MI Okeke, CU Iroegbu, EN Eze, AS Okoli, "Evaluation of extracts of the root of Landolphia owerrience for antibacterial activity", Journal of ethnopharmacology 78 (2-3), 119-127 Esimone, Charles, KF Chah, CA Eze, CE Emuelosi, "Antibacterial and wound healing properties of methanolic extracts of some Nigerian medicinal plants", Journal of ethnopharmacology 104 (1-2), 164-167 Esimone, Charles, CS Nworu, CL Jackson, "Cutaneous wound healing activity of a herbal ointment containing the leaf extract of Jatropha curcas L.(Euphorbiaceae)", International Journal of Applied Research in Natural Products 1 (4), 1-4 Esimone, Charles, IR Iroha, EC Ibezim, CO Okeh, EM Okpana, "In vitro evaluation of the interaction between tea extracts and penicillin G against Staphylococcus aureus", African Journal of Biotechnology 5 (11) Esimone, Charles, PA Ekwealor, MC Ugwu, I Ezeobi, G Amalukwe, BC Ugwu, U Okezie et al., "Antimicrobial evaluation of bacterial isolates from urine specimen of patients with complaints of urinary tract infections in Awka, Nigeria", International journal of microbiology 2016 (1), 9740273
Techniques such as the controlled encapsulation of individual gas bubbles to create hollow nanoparticles for synthesizing microbubbles with specific contents are vital for drug delivery systems. Both silica and titanium-based microparticles are used as durable shells after using gas to increase the flow velocity of the aqueous phase. A higher flow velocity allows greater control over the thickness of the aqueous shells. The emerging versatility of nanoparticles can be seen in the delivery of particle-loaded microdroplets being utilized in depot injections for drug delivery rather than the typical approach of injecting drugs intravenously. This is possible due to the low thickness of the shells which typically are in the range of 1 to 50 μm. More recent advancements in microfluidic particles allowed the synthesis of nanometer sized particles from biologically derived polymers. Using specific flow-focusing multiphase designs that control flow rate and temperature, the size of nanoparticle formation can be controlled along with the concentration and configuration of the droplets. Another technique for creating particle-loaded microdroplets is the use of lipid-hydrogel nanoparticles that can be manipulated into more narrowly shaped droplets, which is useful when soft or brittle materials must be used. These soft materials are especially important in the production of powders.
Sources: en.wikipedia.org
Being zero-dimensional, quantum dots have a sharper density of states than higher-dimensional structures. As a result, they have superior transport and optical properties. They have potential uses in diode lasers, amplifiers, and biological sensors. Quantum dots may be excited within a locally enhanced electromagnetic field produced by gold nanoparticles, which then can be observed from the surface plasmon resonance in the photoluminescent excitation spectrum of (CdSe)ZnS nanocrystals. High-quality quantum dots are well suited for optical encoding and multiplexing applications due to their broad excitation profiles and narrow/symmetric emission spectra. The new generations of quantum dots have far-reaching potential for the study of intracellular processes at the single-molecule level, high-resolution cellular imaging, long-term in vivo observation of cell trafficking, tumor targeting, and diagnostics. CdSe nanocrystals are efficient triplet photosensitizers. Laser excitation of small CdSe nanoparticles enables the extraction of the excited state energy from the quantum dots into bulk solution, thus opening the door to a wide range of potential applications such as photodynamic therapy, photovoltaic devices, molecular electronics, and catalysis.
In enzymology, a peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (EC 3.5.1.52) is an enzyme that catalyzes a chemical reaction that cleaves a N4-(acetyl-beta-D-glucosaminyl)asparagine residue in which the glucosamine residue may be further glycosylated, to yield a (substituted) N-acetyl-beta-D-glucosaminylamine and a peptide containing an aspartate residue. This enzyme belongs to the family of hydrolases, specifically those acting on carbon-nitrogen bonds other than peptide bonds in linear amides. The NGLY1 gene encodes the ortholog of this enzyme in humans.
== Imaging == Via positron emission tomography imaging technique, NET has been selectively investigated. 11C ME@HAPTHI and 18F-MeNER are two NET selective radio tracers for PET imaging. Fluorescent substrates for the transporter can also be used to monitor the transporter rate in isolated organs or tissues, although these are not suitable for clinical imaging.
Sources: en.wikipedia.org
== Clinical translation == Dextran has yet to be approved for any clinical uses in drug delivery due to a wide variety of limitations including heterogeneity, undesirable side effects, and unknown biological pathways. Changes in the molecular weight of dextran have been shown to alter biological activity, indicating a need for separation and purification processes to ensure batch homogeneity. Dextran, although considered relatively safe and nontoxic in vivo, exhibits a few side effects with the most notable being thrombocytopenia and liver toxicity. The exact biological mechanisms by which dextran-based drug delivery systems act on the drug target must be elucidated as well. Dextran-based drug delivery systems have an enormous potential for clinical use in the treatment of a variety of disease states.
The lambdoid suture, or lambdoidal suture, is a dense, fibrous connective tissue joint on the posterior aspect of the skull that connects the parietal bones with the occipital bone. It is continuous with the occipitomastoid suture.
The simple, or top-up transfusion, is a procedure in which healthy blood cells from a donor are infused into the patient's bloodstream. This benefits by alleviating anaemia, increasing tissue oxygen levels, reducing the risk of sickling, and relieving sickling symptoms. A simple transfusion can be used to treat sickle cell disease when haemoglobin levels drop too low, or to prepare for an operation or pregnancy. It can also be used to protect against long-term complications or to reduce the risk of stroke. An exchange transfusion is a procedure in which blood is removed from the body, then processed to extract sickled cells, which are replaced by healthy red blood cells from a donor. The treated blood, including white cells and plasma, is then returned to the patient. Exchange transfusions are likely to be needed in an emergency, in severe cases of sickle cell disease, or to support a mother during pregnancy.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.